This study tested the therapeutic impact of double-loading dose (i.e., 600 mg) versus standard-loading dose (i.e., 300 mg) of clopidogrel on ST-segment-elevation-myocardial-infarction (STEMI) patients undergoing primary-coronary-intervention (PCI).
C ardiovascular disease remains the second leading cause of death worldwide and acute myocardial infarction (AMI) is the leading cause of death from cardiovascular disease. [1] [2] [3] Undoubtedly, early and rapid reperfusion therapy by either thrombolytic therapy or primary coronary intervention (PCI) is the golden standard method for the treatment of acute ST-segment elevation AMI (STEMI). [3] [4] [5] [6] [7] Abundant data have further revealed that primary PCI is superior to thrombolytic therapy in terms of time of reperfusion, reduction in incidence of bleeding complications, recurrent MI and repeated PCI, increasing normal blood flow rate in the infarct-related ar-Tong, ET AL tery (IRA), salvage of jeopardized myocardium, reduction of pump failure and preservation of left ventricular (LV) function, and improving the short-term and long-term outcomes. [8] [9] [10] [11] [12] However, PCI cannot restore normal blood flow to every IRA. In fact, the incidence of the slow flow and no reflow phenomena has been estimated to be around 8% to 15% in real world clinical practice. [6] [7] [8] [12] [13] [14] Importantly, the slow flow and no reflow phenomena in the IRA have been identified to be powerful independent predictors of unfavorable clinical outcomes in STEMI patients undergoing primary PCI. 3, 4, 7, 8, 13) The mechanisms of the slow flow and no reflow have been previously extensively investigated resulting in a global consensus that platelet activation and high-burden thrombus formation are the two most important contributors to these phenomena. 13, 15) Thus, not only mechanical devices (i.e., for removing the thrombus burden) 15, 16) but also the anti-platelet agents (i.e., pharmaceutics for suppressing the platelet reactivity) 15, 17) have been keenly investigated over the past two decades for improving the rate of normal blood flow and inhibiting the incidence of acute or sub-acute in-stent thrombosis.
Therapeutic regimen of double anti-platelet agents for patients with stable angina and acute coronary syndrome (ACS) with or without undergoing PCI/stenting is the cornerstone for improving clinical outcomes. [18] [19] [20] [21] Combined therapy of clopidogrel and aspirin is still recommended by current guidelines as one of the prioritized regimens for patients with ACS undergoing PCI/stenting. 22, 23) Additionally, this regimen for STEMI patients is currently the most popular in the USA. 23) However, drug resistance due to gene polymorphism of CYP2C19 in carriers and inadequate suppression of platelet reactivity in the setting of STEMI undergoing primary PCI resulting in the no reflow phenomenon in IRA and poor prognostic outcome have been reported by many studies. [24] [25] [26] [27] [28] Additionally, the incidence of upper gastrointestinal bleeding (UGIB) which has been less reported in the Asian population is always an issue of concern in STEMI patients after primary PCI. 29) Based on these issues, we designed this study to address 1) whether double-loading the dose of clopidogrel would be superior to the standard-loading dose of clopidogrel (i.e., 600 mg versus 300 mg prior to primary PCI) to reduce the no reflow phenomenon and improve the clinical outcome after primary PCI, and 2) elucidate the incidence of 30-day, one-year and > one-year UGIB in these STEMI patients.
Methods
Patient population: All patients with acute STEMI are considered eligible for primary PCI at our institution. Between January 2005 and December 2013, a total of 1461 STEMI patients presenting with STEMI of < 12 hours' duration undergoing primary PCI were consecutively recruited into the present study. Of these 1461 STEMI patients, 508 patients who were administered 600 mg loading dose of clopidogrel in the emergency room served as group 1 and the remaining 953 patients who received 300 mg loading dose of clopidogrel in the emergency room served as group 2.
Informed consent was obtained from each study subject before undergoing primary PCI. The protocol of this observational study was approved by the Institutional Review Committee on Human Research at our institution (IRB number: 104-7724B).
Reason for different dosage of clopidogrel administration and rationale for grouping: Between January 2005 and December 2007, the standard-loading dose (i.e., 300 mg) was consistently utilized in emergency room in STEMI patients prior to receiving primary PCI. In this contemporary period, the drug resistance had emerged as an important clinical issue in some ACS patients, some experts and limited clinical observation studies suggested that double-loading dose of clopidogrel might be effective on improving angiographic results and reducing an acute thrombosis in IRA. Therefore, either standard-loading dose or double loading dose of clopidogrel was arbitrarily utilized by physicians for the STEMI patients in emergency room prior to primary PCI. Procedure and protocol, and intra-aortic balloon pump and extracorporeal membrane oxygenator support for study patients undergoing primary PCI: Primary PCI was performed according to our previously described protocol. 13, 16, 30) A transradial artery approach utilizing a 6-French arterial sheath is a routine procedure for acute STEMI at our institution unless Allen's test is positive on both sides. A 6-French Kimny guiding catheter (Boston Scientific, Scimed, Maple Grove, MN) was used for both the diagnosis of coronary artery occlusion and primary PCI.
Intra-aortic balloon pump (IABP) support was performed via the right or left femoral arterial approach in patients experiencing acute pulmonary edema associated with unstable condition or hemodynamic instability. Criteria for extracorporeal membrane oxygenation installation : Extracorporeal membrane oxygenation (ECMO) was implemented in the catheterization room for patients whose systolic blood pressure could not be maintained above 75 mmHg after IABP support and intravenous administration of dopamine > 20 μg/kg/minute. The procedure and protocol for ECMO support was described in detail in our previous report. 30) Definitions: The definitions of STEMI and procedural success have been reported in our previous studies. 7, 13, 16, 30) In brief, STEMI was defined as follows: 1) typical chest pain lasting for more than 30 minutes with ST-segment elevation > 1 mm in two consecutive precordial or inferior leads and; 2) typical chest pain lasting for more than 30 minutes with a new-onset complete left bundle branch block. Procedural success was defined as a reduction to residual stenosis of < 20% by balloon angioplasty or successful stent deployment at the desired position with a residual stenosis < 10% followed by thrombolysis in myocardial infarction (TIMI) grade 3 flow in the IRA. Multivessel disease was defined as stenoses of !50% in !2 major epicardial coronary arteries. Advanced Killip score was defined as !Killip score 3 upon presentation and advanced congestive heart failure (CHF) was defined as ! New York Heart Association Functional Class III. 13, 16, 30) Definition of acute kidney injury and upper gastrointestinal bleeding: Acute kidney injury was defined as se-OUTCOME OF DOUBLE-DOSE CLOPIDOGREL IN PCI rum creatinine level either "25% or "0.5 mg/dL from baseline within 72 hours after primary PCI. Additionally, the definition of acute UGIB has been reported in our previous study in details. 29) Briefly, acute UGIB was defined as at least one episode of tarry stool, coffee-ground material in the nasogastric tube > 10 cc, or coffee group emesis was observed in patients. Bleeding from the nasopharyngeal space and oral cavity had to be ruled out in the present study. A diagnostic panendoscopy study was not absolutely required for all the patients as quite number of the patients' conditions did not permit such an investigation.
Primary and Secondary end points:
The primary end points in the present study were angiographic results, acute UGIB during hospitalization, and 30-day mortality. The secondary end points were defined as long-term clinical outcome, incidence of long-term UGIB. Medications: All patients received a loading dose of clopidogrel (i.e., either 600 mg or 300 mg orally) in the emergency room, followed by a maintenance dose (75 mg/day orally once daily) for at least 12 months after primary PCI. In addition, all patients received a loading dose of aspirin (325 mg orally), followed by a maintenance dose (100 mg daily) unless contraindicated. Other commonly prescribed medications also included angiotensinconverting enzyme inhibitors (ACEIs), angiotensin II type I inhibitors (ARBs), statins, beta-blockers, isonitrate, and diuretics. Data collection: The primary PCI program was initiated at our institution in May 1993. For the purpose of this study, all patients undergoing primary PCI were prospectively recruited. Detailed in-hospital and follow-up data including age, gender, coronary risk factors, biochemistry data, Killip score on admission, levels of troponin-I and CK-MB upon presentation, peak level of creatine phosphokinase (CPK), arrival time, duration from puncture to first balloon inflation, reperfusion time, duration of procedure, pre-and post-PCI TIMI flow grades, angiographic results, number of diseased vessels, incidence of UGIB in hospitalization and during clinical follow-up, in-hospital adverse events, and 30-day and one-year mortality were obtained. These data were collected prospectively and entered into a digital database. Statistical analysis: Data were expressed as mean ± SD or percentage of patients. Continuous data were analyzed using t test and categorical data using chi-square or Fisher's exact test, when appropriate. Multivariable logistic regression analysis with stepwise selection was performed to identify independent predictors of 30-day mortality. All statistical analysis was performed using SAS statistical software for Windows version 9.3 (SAS Institute, Cary, NC, USA). A P value of less than 0.05 was considered statistically significant.
Results
Baseline characteristics and clinical features of 1461 study patients (Table I) : The age, prevalence of male gender, and incidence of hypertension, smoking, old stroke and previous myocardial infarction did not differ between group 1 (i.e., clopidogrel loading dose of 600 mg) and group 2 (i.e., clopidogrel loading dose of 300 mg). However, the incidence of diabetes mellitus was significantly lower in group 1 than in group 2.
The body mass index, incidence of end stage renal disease on hemodialysis and history of peptic ulcer were similar between two groups of the patients. Additionally, the incidences of Killip score upon presentation and advanced CHF was also similar among two groups of the patients. Furthermore, the systolic and diastolic blood pressure upon presentation and the incidence of infarction location that was identified by electrocardiogram as well as the incidence of infarct-related artery did not differ between groups 1 and 2. Laboratory measurement results in 1461 study patients (Table II) : Table II shows the laboratory findings of 1461 patients. The circulating levels of white blood cell count, platelet count, hemoglobin, troponin-I and CK-MB upon presentation did not differ between groups 1 and 2. Additionally, the circulating levels of peak creatine kinase phosphatase, Ac sugar, and low-density lipoprotein did not differ between the two groups of the patients. However, the HBA1C level was significantly lower, whereas the high-density lipoprotein level was significantly higher in group 1 than in group 2 patients. Door-to-balloon time, angiographic findings, circulatory mechanical support and 30-day mortality (Table  III) : There were no differences in terms of chest pain onset to emergency room, reperfusion time, and procedure time among two groups. However, the door-to-balloon (DTB) was significantly shorter in group 1 than in group 2 patients.
Angiographic results revealed that the numbers of vessel disease, left main trunk obstruction, rate of pre-PCI TIMI flow, and pre-PCI stenosis rate did not differ among the groups 1 and 2 of the study patients. Additionally, the number of primary PCI vessels in one stage, the residual stenosis and the final TIMI-3 flow also did not differ among the two groups of the patients. The incidence of thrombuster utilization was significantly higher in group 1 than in group 2. However, the incidence of unsuccessful reperfusion (i.e., post-PCI TIMI flow !2) did not differ between the groups. Additionally, the incidence of unsuccessful reperfusion did not differ among patients in group 1 or in group 2 with and without thrombectomy.
The incidence of balloon angioplasty was significantly lower, whereas the incidence of drug eluting stenting was significantly higher in group 1 than in group 2 patients. On the other hand, the requirement for IABP or ECMO support and 30-day mortality rate was similar among the two groups of patients. In-hospital and follow-up untoward clinical outcomes (Table IV) : The incidences of history of previous peptic ulcer, UGIB !30 days, UGIB !one year, and UGIB > one year did not differ among the two groups of patients. Additionally, the incidence of acute kidney injury, and the incidences of recurrence of angina and reinfection during one-year follow up did not differ between these two groups of the patients. Furthermore, the incidence of ischemic stroke either during hospitalization or during one-year flow-up, and the incidence of one-year mortality did not differ among the two groups of study patients.
Tong, ET AL Data are expressed as mean ± SD or n (%). * Group 1 = loading dose of clopidogrel was 600 mg; Group 2 = loading dose of clopidogrel 300 mg. † Advanced Killip score was defined as ≥ score 3; advanced congestive heart failure (CHF) was defined as ≥ New York heart Association Functional Class 3. SBP indicates systolic blood pressure; and DBP, diastolic blood pressure. Tables I to IV were utilized for univariate analysis of the predictors for 30-day mortality. Table V shows only those variables found significant for predicting 30-day mortality. The statistical analyses showed that age, advanced CHF, advanced Killip score, white blood cell count, and creatinine level were the most powerful predictors of 30-day mortality. Additionally, male gender, smoking, previous stroke, reperfusion time, multiple vessel disease and primary PCI for left main (LM) trunk obstruction were also strongly predictive of 30-day mortality.
Multiple stepwise logistic regression analysis demonstrated that age and advanced Killip score were the strongest independent predictors of 30-day mortality. Additionally, circulating white blood cell count and reperfusion time were significant and independent predictors of OUTCOME OF DOUBLE-DOSE CLOPIDOGREL IN PCI Data are expressed as mean ± SD or n (%). *Group 1 = loading dose of clopidogrel was 600 mg; Group 2 = loading dose of clopidogrel 300 mg. † Comparison of % of unsuccessful reperfusion (ie, TIMI flow ≤ 2) between with and without thrombectomy by thrombuster among the group 1 and group 2 patients, respectively. ‡ Statistical analysis individualized among the group 1 and group 2 patients. E/R indicates emergency room; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; BMS, bare metal stent; DES, drug eluting stent; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenator.
30-day mortality.
Association between the different loading dose of clopidogrel and primary and secondary endpoints: Based on the aforementioned results, we found that the primary end points (i.e., final TIMI-3 flow in infarct-related artery, acute UGIB during hospitalization, and 30-day mortality) did not differ between the different loading dose of clopidogrel (i.e., 600 mg versus 300 mg of clopidogrel) among the study patients. Additionally, the secondary endpoints (i.e., the long-term clinical outcome and the incidence of long-term UGIB) in the present study also did not differ between the different loading dose of clopidogrel among the study patients.
Discussion
This study which investigated the impact of a double (i.e., 600 mg) loading regimen of clopidogrel on reducing the no reflow phenomenon and improving the clinical outcome after primary PCI, and further to elucidate the incidence of UGIB in these STEMI patients undergoing dual antiplatelet agents has several clinical implications. First, as compared with the traditional loading regimen (i.e., 300 mg) of clopidogrel, double loading regimen (i.e., 600 mg) of clopidogrel in the emergency room did not offer additional benefit to those of STEMI patients undergoing primary PCI. Second, the incidences of UGIB of ! 30 day, > 30 day ! one year and > one year in the Asian AMI population were relative higher compared with reports of Western AMI population, suggesting racial difference in resistance to damage of the upper gastrointestinal tract by dual antiplatelet agents. Third, age and advanced Killip score were the most powerful and independent predictors of 30-day mortality. Finally, even with a highly Tong, ET AL Data are expressed as n (%). *Group 1 = loading dose of clopidogrel was 600 mg; Group 2 = loading dose of clopidogrel 300 mg. UGIB indicates upper gastrointestinal bleeding. successful rate of perfusion therapy by means of primary PCI, the one-year mortality rate of these patients after discharge from hospital remained higher than 10%, suggesting more aggressive strategic management for these inhospital survival patients should be seriously considered. Double Loading Regimen of clopidogrel did not confer additional benefits on short-term and long-term outcomes in Asian patients with STEMI undergoing primary PCI: Clopidogrel has emerged as a mainstay in the management of patients with acute arterial occlusive syndrome over the past decade, as well as a principal component of PCI pharmacotherapy. [18] [19] [20] [21] [22] [23] However, growing amounts of data have recently shown that poor response (i.e., drug resistance) to clopidogrel as measured by platelet reactivity units or with VerifyNow assay measured in P2Y12 reaction units (PRU) 31, 32) occurs in some ACS patients in real-world clinical practice. [24] [25] [26] This situation, resulting in high-risk thromboembolic events, undoubtedly causes poorer prognostic outcome in patients with ACS undergoing PCI. The results of these experimental and clinical studies [24] [25] [26] 31, 32) raise the question of whether a double dose regimen (i.e., 600 mg) of clopidogrel may improve clinical outcomes in ACS patients undergoing PCI. 33, 34) However, other clinical trials 24, 35) did not find the additional benefit of double regimen of clopidogrel as measured by angiographic findings and clinical outcome as compared to standard loading regimen (i.e., 300 mg) of clopidogrel. This could be mainly because even a high-loading dose of clopidogrel could not overcome the variability of clopidogrel antiplatelet effects between the CYP2C19 *2 carriers and non-carriers in patients treated with PCI. 36) It is well known that the prevalence of gene polymorphism of CYP2C19 *2 carriers is much higher in 7 OUTCOME OF DOUBLE-DOSE CLOPIDOGREL IN PCI Asian populations than in Western populations. Additionally, while the current data from Western patients have shown that the clopidogrel loading dose in management of STEMI patients is still under debate, 37) there is little data to report the impact of clopidogrel loading regimen on angiographic results and clinical outcome in Asian patients with STEMI undergoing primary PCI. 35) The most important finding in the present study was that the angiographic results and clinical outcomes, including the 30-day mortality rate did not differ in double loading regimen of clopidogrel (i.e., 600 mg) from the standard loading regimen of clopidogrel (i.e., 300 mg) in STEM patients undergoing primary PCI. Additionally, when we looked at the one-year mortality rate, the double loading regimen of clopidogrel did not confer any additional benefit as compared with the standard loading regimen. Interestingly, one previous study 35) from Korea (i.e., another Asian country) demonstrated that double loading regimen of clopidogrel was not superior to the standard loading regimen of clopidogrel in terms of reducing one-month and one-year major adverse cardiac event. Accordingly, the results of our study were consistent with the results of the previous study. 35) In fact, a recent experimental study 38) showed that as compared to the standard loading and maintenance regimen of clopidogrel 300/75 mg, high loading and maintenance regimen (600/150 mg) of clopidogrel did not contribute to additional effects on the pharmacodynamics and pharmacokinetics in healthy Japanese subjects (i.e., another Asian country). Accordingly, the results of this and a previous study, 35) in addition to being supported by this study, 38) appear to encourage the use of a standard loading dose of clopidogrel in Asian patients with STEMI undergoing primary PCI for the purpose of cost-effectiveness. Additionally, in gene polymorphism CYP2C19 *2 carriers, ticargrelor or prasugrel, should be considered in Asian STEMI patients because they have been established to have a more potent effect on inhibiting platelet reactivity than that of the clopidogrel. 31, 32) Higher incidence of UGIB in Asian patients than in Western patients after receiving antiplatelet therapy: The incidence of major bleeding and UGIB is always a great concern in the treatment of ACS patients. 18, 24, 39, 40) In the CAPRIE trial, reports of gastrointestinal hemorrhage were 1.99% with clopidogrel and 2.66% with aspirin, respectively. 18, 39) Additionally, in the CURE trial, incidence of gastrointestinal hemorrhage in combined regimen of aspirin and clopidogrel was less than 3.0%. An essential finding in the present study was that the incidences of UGIB at hospitalization, > 30 day ! one year, and > one year were > 8.0%, > 5.0% and, > 9.0%, respectively, much higher than in Western patients. 18, 24, 39, 40) Our previous study 29) also revealed that the incidence of in-hospital UGIB was 8.9% in STEMI patients undergoing primary PCI. Accordingly, the findings of our two studies were consistent. On the other hand, we remain uncertain about why the incidence of UGIB complication was substantially higher in the Asian population than in the Western population with an identical antiplatelet regimen. Perhaps, racial difference is the major contributor to this adverse event. This finding suggests the use of more aggressive management, such as using PPI agents, for the high-risk group of STEMI patients undergoing primary PCI in our future clinical practice. Independent risk predictor of poor prognostic outcomes: Abundant data have shown that inflammatory biomarkers are strongly and independently predictive of poor prognostic outcome in STEMI patients undergoing primary PCI. 14, 41, 42) Additionally, age, 43) unsuccessful reperfusion 7, 13) and advanced Killip score 30) have been identified as independent predictors of poor prognostic outcome in those of STEMI patients receiving primary PCI. A principal finding in the present study was that the above parameters were found to be independently predictive of 30-day mortality. These findings reinforce the findings of previous studies. 7, 13, 14, 41, 43, 44) Study Limitation: This study had several limitations. First, although the data were prospectively collected from our primary PCI program, the study was investigated in a retrospective manner. Second, the patients were not randomized to receive 600 mg versus 300 mg of clopidogrel in this study. Third, although we carefully identified the possibility of UGIB events in our study patients, bias caused by missing this complication could not be completely ruled out. Thus, the incidence of UGIB during hospitalization and after uneventful discharge could be underestimated in the present study.
In conclusion, the results of this study demonstrated that pre-PCI double loading regimen of clopidogrel did not offer an additional benefit to patients with STEMI undergoing primary PCI. The incidence of UGIB complication was considerably increased in Asian patients in comparison with Western patients with STEMI undergoing primary PCI, highlighting the necessity for appropriate strategic management in our setting.
